UBS Group Initiates Coverage on Altimmune (NASDAQ:ALT)

UBS Group started coverage on shares of Altimmune (NASDAQ:ALT) in a report released on Tuesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $26.00 price target on the stock. UBS Group’s target price would suggest a potential upside of 173.11% from the company’s current price.

A number of other equities research analysts also recently commented on the company. B. Riley reaffirmed a “buy” rating and set a $20.00 target price on shares of Altimmune in a report on Monday, August 12th. Evercore ISI upgraded shares of Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research note on Thursday, August 22nd. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Altimmune has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Altimmune Stock Up 0.3 %

Shares of Altimmune stock opened at $9.52 on Tuesday. The company has a market cap of $676.59 million, a P/E ratio of -6.14 and a beta of 0.09. The firm’s 50 day moving average price is $6.95 and its 200-day moving average price is $6.89. Altimmune has a 52-week low of $2.34 and a 52-week high of $14.84.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 52.60% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million for the quarter. During the same quarter last year, the firm earned ($0.39) earnings per share. As a group, equities research analysts forecast that Altimmune will post -0.54 EPS for the current fiscal year.

Insider Transactions at Altimmune

In other news, Director David Drutz sold 16,011 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the transaction, the director now directly owns 41,958 shares in the company, valued at $289,510.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ALT. BNP Paribas Financial Markets boosted its stake in Altimmune by 318.6% during the third quarter. BNP Paribas Financial Markets now owns 42,140 shares of the company’s stock worth $259,000 after buying an additional 32,072 shares during the period. FMR LLC boosted its position in shares of Altimmune by 546.8% during the 3rd quarter. FMR LLC now owns 51,060 shares of the company’s stock worth $314,000 after purchasing an additional 43,166 shares during the period. Summit Financial Wealth Advisors LLC boosted its position in shares of Altimmune by 65.1% during the 3rd quarter. Summit Financial Wealth Advisors LLC now owns 45,918 shares of the company’s stock worth $282,000 after purchasing an additional 18,113 shares during the period. Larson Financial Group LLC acquired a new stake in Altimmune in the 3rd quarter valued at approximately $31,000. Finally, Charles Schwab Investment Management Inc. raised its position in Altimmune by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after purchasing an additional 4,772 shares during the period. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.